A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept and laser for retinopathy of prematurity
<p><strong>Topic:</strong> To compare bevacizumab, ranibizumab, aflibercept and laser as primary therapies for retinopathy of prematurity (ROP) in terms of retreatment rate.</p> <p><strong>Clinical relevance:</strong> Anti-VEGF agents are increasingly used...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2022
|